Clinical outcome and costs of nosocomial and community-acquired Staphylococcus aureus bloodstream infection in haemodialysis patients

Greiner W, Rasch A, Koehler D, Salzberger B, Faetkenheuer G, Leidig M (2007)
CLINICAL MICROBIOLOGY AND INFECTION 13(3): 264-268.

Journal Article | Published | English

No fulltext has been uploaded

Author
; ; ; ; ;
Abstract
The main aim of this study was to evaluate the clinical outcome and costs of nosocomial and community-acquired methicillin-susceptible Staphylococcus aureus (MSSA) or methicillin-resistant S. aureus (MRSA) bloodstream infection (BSI) in patients undergoing haemodialysis. A multicentre retrospective study was conducted that included 109 patients with end-stage renal disease and S. aureus BSI who were hospitalised in three German centres between 1999 and 2005. Nosocomial and community-acquired infections were analysed separately with regard to costs and outcome. Forty-nine (45%) patients had nosocomial infection. Compared to patients with community-acquired infection, these patients were more likely to have had BSI caused by MRSA (40.8% vs. 13.3%, p < 0.05). BSI was the initial reason for admission for 33 (55%) patients who had community-acquired infection. The mean length of hospitalisation was 24 days for patients with community-acquired infection and 51 days for patients with nosocomial infection (p < 0.05). Costs per treatment episode were 20 024 Euros for nosocomial infection vs. 9554 Euros for community-acquired infection (p < 0.05). The average treatment costs for patients with MSSA BSI were < 50% of those for patients with MRSA BSI (10 573 vs. 24 931 Euros, p < 0.05). S. aureus BSI is an underlying cause of substantial health risk and high morbidity among the haemodialysis-dependent population, who are already at high-risk for other reasons. This study also highlighted differences according to the source of BSI, including costs arising from hospitalisation and treatment.
Publishing Year
ISSN
eISSN
PUB-ID

Cite this

Greiner W, Rasch A, Koehler D, Salzberger B, Faetkenheuer G, Leidig M. Clinical outcome and costs of nosocomial and community-acquired Staphylococcus aureus bloodstream infection in haemodialysis patients. CLINICAL MICROBIOLOGY AND INFECTION. 2007;13(3):264-268.
Greiner, W., Rasch, A., Koehler, D., Salzberger, B., Faetkenheuer, G., & Leidig, M. (2007). Clinical outcome and costs of nosocomial and community-acquired Staphylococcus aureus bloodstream infection in haemodialysis patients. CLINICAL MICROBIOLOGY AND INFECTION, 13(3), 264-268.
Greiner, W., Rasch, A., Koehler, D., Salzberger, B., Faetkenheuer, G., and Leidig, M. (2007). Clinical outcome and costs of nosocomial and community-acquired Staphylococcus aureus bloodstream infection in haemodialysis patients. CLINICAL MICROBIOLOGY AND INFECTION 13, 264-268.
Greiner, W., et al., 2007. Clinical outcome and costs of nosocomial and community-acquired Staphylococcus aureus bloodstream infection in haemodialysis patients. CLINICAL MICROBIOLOGY AND INFECTION, 13(3), p 264-268.
W. Greiner, et al., “Clinical outcome and costs of nosocomial and community-acquired Staphylococcus aureus bloodstream infection in haemodialysis patients”, CLINICAL MICROBIOLOGY AND INFECTION, vol. 13, 2007, pp. 264-268.
Greiner, W., Rasch, A., Koehler, D., Salzberger, B., Faetkenheuer, G., Leidig, M.: Clinical outcome and costs of nosocomial and community-acquired Staphylococcus aureus bloodstream infection in haemodialysis patients. CLINICAL MICROBIOLOGY AND INFECTION. 13, 264-268 (2007).
Greiner, Wolfgang, Rasch, A., Koehler, D., Salzberger, B., Faetkenheuer, G., and Leidig, M. “Clinical outcome and costs of nosocomial and community-acquired Staphylococcus aureus bloodstream infection in haemodialysis patients”. CLINICAL MICROBIOLOGY AND INFECTION 13.3 (2007): 264-268.
This data publication is cited in the following publications:
This publication cites the following data publications:

15 Citations in Europe PMC

Data provided by Europe PubMed Central.

Memory Th1 Cells Are Protective in Invasive Staphylococcus aureus Infection.
Brown AF, Murphy AG, Lalor SJ, Leech JM, O'Keeffe KM, Mac Aogain M, O'Halloran DP, Lacey KA, Tavakol M, Hearnden CH, Fitzgerald-Hughes D, Humphreys H, Fennell JP, van Wamel WJ, Foster TJ, Geoghegan JA, Lavelle EC, Rogers TR, McLoughlin RM., PLoS Pathog. 11(11), 2015
PMID: 26539822
Risk factors for morbidity and mortality of bloodstream infection in patients undergoing hemodialysis: a nested case-control study.
Fram D, Taminato M, Ponzio V, Manfredi SR, Grothe C, Batista RE, Belasco A, Barbosa D., BMC Res Notes 7(), 2014
PMID: 25481650
Impact of antimicrobial multidrug resistance on inpatient care cost: an evaluation of the evidence.
Tansarli GS, Karageorgopoulos DE, Kapaskelis A, Falagas ME., Expert Rev Anti Infect Ther 11(3), 2013
PMID: 23458771
Staphylococcus aureus-derived extracellular vesicles induce neutrophilic pulmonary inflammation via both Th1 and Th17 cell responses.
Kim MR, Hong SW, Choi EB, Lee WH, Kim YS, Jeon SG, Jang MH, Gho YS, Kim YK., Allergy 67(10), 2012
PMID: 22913540
The potential economic value of a Staphylococcus aureus vaccine among hemodialysis patients.
Song Y, Tai JH, Bartsch SM, Zimmerman RK, Muder RR, Lee BY., Vaccine 30(24), 2012
PMID: 22464963
Infectious complications in dialysis--epidemiology and outcomes.
Li PK, Chow KM., Nat Rev Nephrol 8(2), 2012
PMID: 22183504
Management of gram-positive coccal bacteremia and hemodialysis.
Fitzgibbons LN, Puls DL, Mackay K, Forrest GN., Am. J. Kidney Dis. 57(4), 2011
PMID: 21333430
High-dose cefazolin on consecutive hemodialysis in anuric patients with Staphylococcal bacteremia.
Renaud CJ, Lin X, Subramanian S, Fisher DA., Hemodial Int 15(1), 2011
PMID: 21105995
Management of Gram-positive bacteraemia.
Uckay I, Harbarth S, Pittet D., Curr. Opin. Infect. Dis. 20(6), 2007
PMID: 17975404

29 References

Data provided by Europe PubMed Central.

EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients.
Hoen B, Paul-Dauphin A, Hestin D, Kessler M., J. Am. Soc. Nephrol. 9(5), 1998
PMID: 9596085
Risk factor analysis for long-term tunneled dialysis catheter-related bacteremias.
Jean G, Charra B, Chazot C, Vanel T, Terrat JC, Hurot JM, Laurent G., Nephron 91(3), 2002
PMID: 12119469
Preventing bacterial infections and antimicrobial resistance in dialysis patients.
Berns JS, Tokars JI., Am. J. Kidney Dis. 40(5), 2002
PMID: 12407632

Export

0 Marked Publications

Open Data PUB

Web of Science

View record in Web of Science®

Sources

PMID: 17391380
PubMed | Europe PMC

Search this title in

Google Scholar